Kiora Pharmaceuticals
KPRX
9 hedge funds and large institutions have $2.4M invested in Kiora Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
80% more funds holding
Funds holding: 5 → 9 (+4)
0% less ownership
Funds ownership: 0% → 0% (-0%)
21% less capital invested
Capital invested by funds: $3.06M → $2.4M (-$656K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$38.2K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$38.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.5K |
| 4 |
VF
Virtu Financial
New York
|
+$19.1K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
+$12.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$350K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $1.89M | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $314K | +$25.5K | +4 | +9% |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $54K | -$350K | -55 | -86% |
|
|
TSS
4
Two Sigma Securities
New York
| $37K | +$38.2K | +6 | New |
|
|
CS
5
Credit Suisse
Zurich,
Switzerland
| $35K | +$38.2K | +6 | New |
|
|
IA
6
IFP Advisors
Tampa,
Florida
| $30K | +$12.7K | +2 | +67% |
|
|
VF
7
Virtu Financial
New York
| $19K | +$19.1K | +3 | New |
|
8
Northern Trust
Chicago,
Illinois
| $13K | +$12.7K | +2 | New |
|
|
VIA
9
Vantage Investment Advisors
State College,
Pennsylvania
| $8K | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
11
BlackRock
New York
| $1K | – | – | – |
|
12
Morgan Stanley
New York
| $1K | – | – | – |
|
KPRX Hedge Fund Activity: Q3 2017 in Review
9 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2017, worth a combined $2.4M — down 21% from $3.06M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KPRX positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $38.2K. The largest seller was Sabby Management, cutting an estimated $350K.
- 9 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2017, up from 5 in Q2 2017.
- Funds reported $2.4M of Kiora Pharmaceuticals stock for Q3 2017, down 21% quarter-over-quarter.
- 4 funds opened new Kiora Pharmaceuticals positions in Q3 2017 and 0 closed out, a net change of +4 holders.
- The largest Kiora Pharmaceuticals buyer in Q3 2017 was Credit Suisse, an estimated $38.2K added.
- The largest Kiora Pharmaceuticals seller in Q3 2017 was Sabby Management, an estimated $350K sold.
Based on aggregated 13F filings for Q3 2017.